FBXO40

Across TCGA pan-cancer cohorts, FBXO40 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FBXO40 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FBXO40 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO40 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, HNSC, and UCEC are the cancer types where FBXO40 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
HNSC	OS	Median	All	0.348	0.663	.024	18	view →
UCEC	DFS	Median	II,III,IV	0.928	0.434	.017	14	view →
SKCM	DFS	Median	III,IV	0.828	0.477	.006	10	view →
COAD	DFS	Median	All	0.189	0.507	.011	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.629	.027	4	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FBXO40–ACC (DFS)

Open the ACC breakdown →